Proteomics Panel Not Useful for Predicting Hypertensive Disorders of Pregnancy
By Elana Gotkine HealthDay Reporter
THURSDAY, July 11, 2024 -- Large-scale proteomics in early pregnancy is not clinically useful for risk prediction of hypertensive disorders of pregnancy (HDP), according to a study published online July 3 in JAMA Cardiology.
Philip Greenland, M.D., from the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues conducted a nested case-control study to examine the predictive ability of large-scale proteomics for prediction of HDP in early pregnancy. Nulliparous individuals during first-trimester clinical visits were included; cases were those with HDP, while controls were selected from those who delivered at or after 37 weeks without any HDP, preterm birth, or small-for-gestational-age infants. Data were included for 753 HDP cases and 1,097 controls. An aptamer-based assay that included 6,481 unique human proteins was performed on stored plasma.
The elastic net model was used to adjust protein-based models for clinical and demographic variables. Using this approach, the researchers found no proteins were selected for augmenting the clinical and demographic covariates. Modest predictive performance was seen for the resulting model, with areas under the curve of 0.64 and 0.62 for the training and test sets, respectively. Only minimal changes were yielded with further adjustment for study site.
"In this case-control study with detailed clinical data and stored plasma samples available in the first trimester, an aptamer-based proteomics panel did not meaningfully add to predictive utility over and above clinical and demographic factors that are routinely available," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Hypertensive Disorders of Pregnancy Adversely Affect Preemie Neurodevelopment
THURSDAY, May 1, 2025 -- Maternal hypertensive disorders of pregnancy (HDP) are associated with adverse cognitive and language development in preterm infants at 2 years' corrected...
Lorundrostat Beneficial for BP Reduction in Uncontrolled Hypertension
WEDNESDAY, April 30, 2025 -- For patients with uncontrolled and treatment-resistant hypertension, lorundrostat is associated with greater reductions in blood pressure than...
Intensive BP Reduction Effective for Lowering All-Cause Dementia Risk
TUESDAY, April 29, 2025 -- An intensive blood pressure (BP) reduction intervention is effective for lowering the risk for all-cause dementia among individuals aged 40 years and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.